Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Tandem Diabetes CareLTS:0M0F -3.92%68 3-Year EBITDA Growth Rate is -31.40% as of Jun. 2026. GuruFocus rates LTS:0M0F with a GF Score™ of 68/100 and a GF Value™ of $24.82 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 687 Medical Devices & Instruments companies, Tandem Diabetes Care ranks worse than 91.85% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was -31.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Tandem Diabetes Care was 76.20% per year. The lowest was -138.10% per year. And the median was 16.40% per year.
Tandem Diabetes Care (LTS:0M0F) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Tandem Diabetes Care 3-Year EBITDA Growth Rate Related Terms
LTS:0M0F vs CNMD, ATEC, ENOV: 3-Year EBITDA Growth Rate Comparison
For the Medical Devices subindustry, Tandem Diabetes Care's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tandem Diabetes Care 3-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Tandem Diabetes Care's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Tandem Diabetes Care's 3-Year EBITDA Growth Rate falls into.
Tandem Diabetes Care 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of -31.40% mean?
Tandem Diabetes Care (LTS:0M0F) has a 3-Year EBITDA Growth Rate of -31.40% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Tandem Diabetes Care and its competitors. According to the industry distribution chart, Tandem Diabetes Care ranks #631 out of 687 companies in the Medical Devices & Instruments industry, placing it in the top 91.8%.
Is Tandem Diabetes Care's 3-Year EBITDA Growth Rate too high?
Tandem Diabetes Care's current 3-Year EBITDA Growth Rate is -31.40%. Based on the distribution chart, Tandem Diabetes Care ranks #631 out of 687 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Tandem Diabetes Care has a GF Score™ of 68/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Tandem Diabetes Care's 3-Year EBITDA Growth Rate compare to CNMD and ATEC?
According to the Medical Devices & Instruments industry distribution chart, Tandem Diabetes Care ranks #631 out of 687 companies for 3-Year EBITDA Growth Rate. This places Tandem Diabetes Care in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 8.10. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EBITDA Growth Rate among Medical Devices & Instruments companies is 8.10, based on 687 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Tandem Diabetes Care and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EBITDA Growth Rate is 8.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tandem Diabetes Care's current 3-Year EBITDA Growth Rate is -31.40%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tandem Diabetes Care stock overvalued right now?
Based on GuruFocus' analysis, Tandem Diabetes Care (LTS:0M0F) is currently considered Modestly Undervalued. The stock's GF Value™ is $24.82, compared to a current price of $17.64 — trading 28.9% below its estimated fair value. The current 3-Year EBITDA Growth Rate is -31.40%. Tandem Diabetes Care's overall GF Score™ is 68/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Tandem Diabetes Care (LTS:0M0F), the current 3-Year EBITDA Growth Rate is -31.40% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tandem Diabetes Care (LTS:0M0F) Overvalued in 2026?
Based on GuruFocus' analysis, Tandem Diabetes Care stock appears to be undervalued.
The current stock price of $17.64 is trading 28.9% below its estimated GF Value™ of $24.82.
GuruFocus considers Tandem Diabetes Care to be Modestly Undervalued.
Key valuation signals for LTS:0M0F:
3-Year EBITDA Growth Rate: -31.40%
GF Value™: $24.82 vs. price of $17.64 (28.9% below fair value)
No single metric tells the full story. See the LTS:0M0F stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for individuals with diabetes. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on Tobi (a tubeless version of Mobi), and the Sigi tubeless patch pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one-third is from disposable infusion sets that need to be changed over every 2 to 3 days.
68GF Score
Get the complete analysis for LTS:0M0F
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0M0F has been successfully added to your 
